BEAT
HeartBeam, Inc.
Medical - Healthcare Information Services
Market Cap$36M
5Y Perf.-75.1%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
BEAT vs HSDT vs IDXX vs LIVN
Revenue, margins, valuation, and 5-year total return — side by side.
HSDT
Solana Company
Medical - Devices
Market Cap$89M
5Y Perf.-100.0%
IDXX
IDEXX Laboratories, Inc.
Medical - Diagnostics & Research
Market Cap$44.49B
5Y Perf.-7.9%
LIVN
LivaNova PLC
Medical - Devices
Market Cap$3.95B
5Y Perf.-10.4%
BEAT vs HSDT vs IDXX vs LIVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BEAT | HSDT | IDXX | LIVN |
|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Devices | Medical - Diagnostics & Research | Medical - Devices |
| Market Cap | $36M | $89M | $44.49B | $3.95B |
| Revenue (TTM) | $0.00 | $6M | $4.45B | $1.43B |
| Net Income (TTM) | $-21M | $-41M | $1.10B | $107M |
| Gross Margin | — | 91.7% | 62.1% | 67.5% |
| Operating Margin | — | -351.0% | 31.6% | 13.4% |
| Forward P/E | — | — | 38.3x | 16.9x |
| Total Debt | $0.00 | $0.00 | $1.08B | $473M |
| Cash & Equiv. | $4M | $7M | $180M | $636M |
BEAT vs HSDT vs IDXX vs LIVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BEAT
HSDT
IDXX
LIVN
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| HeartBeam, Inc. (BEAT) | 100 | 24.9 | -75.1% |
| Solana Company (HSDT) | 100 | 0.0 | -100.0% |
| IDEXX Laboratories,… (IDXX) | 100 | 92.1 | -7.9% |
| LivaNova PLC (LIVN) | 100 | 89.6 | -10.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BEAT vs HSDT vs IDXX vs LIVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IDXX and LIVN are tied at the top with 2 categories each — the right choice depends on your priorities. LivaNova PLC is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. BEAT and HSDT also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
BEAT
HeartBeam, Inc.
The Income Pick
BEAT is the clearest fit if your priority is income & stability.
- beta 1.27
- Beta 1.27 vs HSDT's 2.65
Best for: income & stability
HSDT
Solana Company
The Growth Play
HSDT is the clearest fit if your priority is growth exposure.
- Rev growth 10.6%, EPS growth 57.3%, 3Y rev CAGR 97.0%
- 10.6% revenue growth vs BEAT's -100.0%
Best for: growth exposure
IDXX
IDEXX Laboratories, Inc.
The Long-Run Compounder
IDXX has the current edge in this matchup, primarily because of its strength in long-term compounding.
- 5.4% 10Y total return vs LIVN's 48.1%
- 24.6% margin vs HSDT's -6.8%
- 32.6% ROA vs BEAT's -353.1%
Best for: long-term compounding
LIVN
LivaNova PLC
The Defensive Pick
LIVN is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 1.33, Low D/E 39.4%, current ratio 1.36x
- Beta 1.33, current ratio 1.36x
- Lower P/E (16.9x vs 38.3x)
- +63.1% vs HSDT's -99.0%
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HSDT | 10.6% revenue growth vs BEAT's -100.0% |
| Value | LIVN | Lower P/E (16.9x vs 38.3x) |
| Quality / Margins | IDXX | 24.6% margin vs HSDT's -6.8% |
| Stability / Safety | BEAT | Beta 1.27 vs HSDT's 2.65 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | LIVN | +63.1% vs HSDT's -99.0% |
| Efficiency (ROA) | IDXX | 32.6% ROA vs BEAT's -353.1% |
BEAT vs HSDT vs IDXX vs LIVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2019
FY 2025
FY 2025
FY 2025
BEAT vs HSDT vs IDXX vs LIVN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLIVNLAGGINGHSDT
Who Leads Where
LIVN leads in 2 of 6 categories
IDXX leads 1 • BEAT leads 0 • HSDT leads 0 • 2 tied
Explore the data ↓HSDTSolana Company
0leads
BEATHeartBeam, Inc.
0leads
IDXXIDEXX Laboratories, I…
1leads
LIVNLivaNova PLC
2leads
6 Total Categories
CATEGORYLEADERvs IDXXvs BEATMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
LIVN5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IDXX6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
LIVN4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — HSDT and IDXX each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IDXX and BEAT operate at a comparable scale, with $4.4B and $0 in trailing revenue. IDXX is the more profitable business, keeping 24.6% of every revenue dollar as net income compared to HSDT's -6.8%. On growth, HSDT holds the edge at +33.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | BEATHeartBeam, Inc. | HSDTSolana Company | IDXXIDEXX Laboratorie… | LIVNLivaNova PLC |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $6M | $4.4B | $1.4B |
| EBITDAEarnings before interest/tax | -$21M | -$21M | $1.5B | $220M |
| Net IncomeAfter-tax profit | -$21M | -$41M | $1.1B | $107M |
| Free Cash FlowCash after capex | -$15M | -$17M | $845M | $161M |
| Gross MarginGross profit ÷ Revenue | — | +91.7% | +62.1% | +67.5% |
| Operating MarginEBIT ÷ Revenue | — | -3.5% | +31.6% | +13.4% |
| Net MarginNet income ÷ Revenue | — | -6.8% | +24.6% | +7.5% |
| FCF MarginFCF ÷ Revenue | — | -2.7% | +19.0% | +11.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +33.4% | +14.3% | +14.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +22.2% | +3.9% | +16.6% | +106.7% |
Evenly matched — HSDT and IDXX each lead in 3 of 6 comparable metrics.
Valuation Metrics
LIVN leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, LIVN's 15.7x EV/EBITDA is more attractive than IDXX's 30.9x.
| Metric | BEATHeartBeam, Inc. | HSDTSolana Company | IDXXIDEXX Laboratorie… | LIVNLivaNova PLC |
|---|---|---|---|---|
| Market CapShares × price | $36M | $89M | $44.5B | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $31M | $82M | $45.4B | $3.8B |
| Trailing P/EPrice ÷ TTM EPS | -1.44x | -1.20x | 42.82x | -16.15x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 38.29x | 16.92x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 3.00x | — |
| EV / EBITDAEnterprise value multiple | — | — | 30.95x | 15.68x |
| Price / SalesMarket cap ÷ Revenue | — | 14.87x | 10.34x | 2.84x |
| Price / BookPrice ÷ Book value/share | 11.53x | 0.16x | 28.15x | 3.26x |
| Price / FCFMarket cap ÷ FCF | — | — | 42.23x | 22.79x |
LIVN leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
IDXX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
IDXX delivers a 70.9% return on equity — every $100 of shareholder capital generates $71 in annual profit, vs $-6 for BEAT. LIVN carries lower financial leverage with a 0.39x debt-to-equity ratio, signaling a more conservative balance sheet compared to IDXX's 0.67x. On the Piotroski fundamental quality scale (0–9), IDXX scores 7/9 vs BEAT's 1/9, reflecting strong financial health.
| Metric | BEATHeartBeam, Inc. | HSDTSolana Company | IDXXIDEXX Laboratorie… | LIVNLivaNova PLC |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -5.7% | -105.0% | +70.9% | +9.1% |
| ROA (TTM)Return on assets | -3.5% | -20.7% | +32.6% | +4.2% |
| ROICReturn on invested capital | — | -10.8% | +42.5% | +11.5% |
| ROCEReturn on capital employed | -4.6% | -14.0% | +61.4% | +10.2% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 | 7 | 5 |
| Debt / EquityFinancial leverage | — | — | 0.67x | 0.39x |
| Net DebtTotal debt minus cash | -$4M | -$7M | $897M | -$162M |
| Cash & Equiv.Liquid assets | $4M | $7M | $180M | $636M |
| Total DebtShort + long-term debt | $0 | $0 | $1.1B | $473M |
| Interest CoverageEBIT ÷ Interest expense | — | -63.39x | 35.55x | 5.18x |
IDXX leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
LIVN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IDXX five years ago would be worth $10,663 today (with dividends reinvested), compared to $0 for HSDT. Over the past 12 months, LIVN leads with a +63.1% total return vs HSDT's -99.0%. The 3-year compound annual growth rate (CAGR) favors LIVN at 15.1% vs HSDT's -92.8% — a key indicator of consistent wealth creation.
| Metric | BEATHeartBeam, Inc. | HSDTSolana Company | IDXXIDEXX Laboratorie… | LIVNLivaNova PLC |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -63.4% | -28.2% | -16.4% | +18.5% |
| 1-Year ReturnPast 12 months | -50.8% | -99.0% | +14.3% | +63.1% |
| 3-Year ReturnCumulative with dividends | -58.2% | -100.0% | +15.4% | +52.5% |
| 5-Year ReturnCumulative with dividends | -81.0% | -100.0% | +6.6% | -13.3% |
| 10-Year ReturnCumulative with dividends | -81.0% | -100.0% | +542.3% | +48.1% |
| CAGR (3Y)Annualised 3-year return | -25.2% | -92.8% | +4.9% | +15.1% |
LIVN leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BEAT and LIVN each lead in 1 of 2 comparable metrics.
Risk & Volatility
BEAT is the less volatile stock with a 1.27 beta — it tends to amplify market swings less than HSDT's 2.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 99.1% from its 52-week high vs HSDT's 0.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BEATHeartBeam, Inc. | HSDTSolana Company | IDXXIDEXX Laboratorie… | LIVNLivaNova PLC |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 2.65x | 1.36x | 1.33x |
| 52-Week HighHighest price in past year | $4.00 | $258.50 | $769.98 | $72.50 |
| 52-Week LowLowest price in past year | $0.54 | $1.61 | $485.41 | $41.02 |
| % of 52W HighCurrent price vs 52-week peak | +22.3% | +0.9% | +72.7% | +99.1% |
| RSI (14)Momentum oscillator 0–100 | 39.0 | 54.2 | 49.2 | 65.0 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 295K | 535K | 802K |
Evenly matched — BEAT and LIVN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: IDXX as "Buy", LIVN as "Buy". Consensus price targets imply 33.5% upside for IDXX (target: $748) vs 10.3% for LIVN (target: $79).
| Metric | BEATHeartBeam, Inc. | HSDTSolana Company | IDXXIDEXX Laboratorie… | LIVNLivaNova PLC |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $747.50 | $79.25 |
| # AnalystsCovering analysts | — | — | 22 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +2.7% | +0.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
LIVN leads in 2 of 6 categories (Valuation Metrics, Total Returns). IDXX leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallLivaNova PLC (LIVN)Leads 2 of 6 categories
Loading custom metrics...
BEAT vs HSDT vs IDXX vs LIVN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BEAT or HSDT or IDXX or LIVN a better buy right now?
For growth investors, Solana Company (HSDT) is the stronger pick with 1057% revenue growth year-over-year, versus 10.
4% for IDEXX Laboratories, Inc. (IDXX). IDEXX Laboratories, Inc. (IDXX) offers the better valuation at 42. 8x trailing P/E (38. 3x forward), making it the more compelling value choice. Analysts rate IDEXX Laboratories, Inc. (IDXX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BEAT or HSDT or IDXX or LIVN?
On forward P/E, LivaNova PLC is actually cheaper at 16.
9x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — BEAT or HSDT or IDXX or LIVN?
Over the past 5 years, IDEXX Laboratories, Inc.
(IDXX) delivered a total return of +6. 6%, compared to -100. 0% for Solana Company (HSDT). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus HSDT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BEAT or HSDT or IDXX or LIVN?
By beta (market sensitivity over 5 years), HeartBeam, Inc.
(BEAT) is the lower-risk stock at 1. 27β versus Solana Company's 2. 65β — meaning HSDT is approximately 108% more volatile than BEAT relative to the S&P 500. On balance sheet safety, LivaNova PLC (LIVN) carries a lower debt/equity ratio of 39% versus 67% for IDEXX Laboratories, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BEAT or HSDT or IDXX or LIVN?
By revenue growth (latest reported year), Solana Company (HSDT) is pulling ahead at 1057% versus 10.
4% for IDEXX Laboratories, Inc. (IDXX). On earnings-per-share growth, the picture is similar: Solana Company grew EPS 57. 3% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, HSDT leads at 97. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BEAT or HSDT or IDXX or LIVN?
IDEXX Laboratories, Inc.
(IDXX) is the more profitable company, earning 24. 6% net margin versus -679. 6% for Solana Company — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus -351. 0% for HSDT. At the gross margin level — before operating expenses — HSDT leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BEAT or HSDT or IDXX or LIVN more undervalued right now?
On forward earnings alone, LivaNova PLC (LIVN) trades at 16.
9x forward P/E versus 38. 3x for IDEXX Laboratories, Inc. — 21. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IDXX: 33. 5% to $747. 50.
08Which pays a better dividend — BEAT or HSDT or IDXX or LIVN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is BEAT or HSDT or IDXX or LIVN better for a retirement portfolio?
For long-horizon retirement investors, IDEXX Laboratories, Inc.
(IDXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+542. 3% 10Y return). Solana Company (HSDT) carries a higher beta of 2. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IDXX: +542. 3%, HSDT: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BEAT and HSDT and IDXX and LIVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BEAT is a small-cap quality compounder stock; HSDT is a small-cap high-growth stock; IDXX is a mid-cap quality compounder stock; LIVN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.